Maravai unit TriLink wins China patent for CleanCap mRNA capping technology

• Maravai LifeSciences’ TriLink unit secured a newly issued China patent for CleanCap mRNA capping technology, strengthening IP protection in a key market.
• Patent ZL 2025 1 1246578.X covers co-transcriptional RNA synthesis methods using trimer or tetramer capping structures across the CleanCap analog suite.
• Coverage includes the latest M6 analog, extending protection for technology used in commercial COVID-19 mRNA and saRNA vaccines.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maravai LifeSciences Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260720933381) on July 20, 2026, and is solely responsible for the information contained therein.